A Phase III Randomised Double -Blind Active-controlled Study to Assess the Efficacy Safety and Tolerability of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone on Chronic Kidney Disease (CKD) Progression in Participants with CKD and High Blood Pressure

Brief description of study

The purpose of this study to learn more about the benefits and safety of treatment with a drug called baxdrostat in combination with dapagliflozin in patients with Chronic Kidney Disease (CKD) and high blood pressure and also to better understand the studied disease and associated health problems.

Clinical Study Identifier: s24-00432

ClinicalTrials.gov Identifier: NCT06268873

Principal Investigator: David Michael Charytan.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies